EquityZen Growth Technology Fund LLC - Series 837
Raised
$458K
Investors
25
Min Invest
$9,994
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 837 is a pooled investment fund filed by EquityZen Advisors LLC that raised $458K from 25 investors with a $10K minimum investment under Regulation D exemptions 506(b) and 3(c)(1). This Delaware LLC is part of the EquityZen platform, which operates nearly 1,900 related entities focused on pre-IPO secondary market access.
This pre-IPO fund uses the standard 506(b)/3(c)(1) exemption pairing common to private investment vehicles targeting accredited investors, with a $10K minimum investment representing the accessible retail-accredited tier. The filing reflects EquityZen's platform model of creating individual series LLCs for discrete pre-IPO company positions.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Richard Thoms
Executive Officer · Salt Lake City, UT
Assure Fund Management II LLC
Director · Salt Lake City, UT
Philip Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.